Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00834899 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of Eptifibatide in Patients With Sickle Cell Disease
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00834899 is a Phase 1 study that was terminated before completion, run by University of North Carolina, Chapel Hill. The registered enrollment target is 13 participants.
The verdict
NCT00834899, a Phase 1 study, was terminated before completion, sponsored by University of North Carolina, Chapel Hill.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study will evaluate the safety of eptifibatide in sickle cell patients and how well it works during the course of painful crises. The overall hypothesis that we seek to test is that increased platelet activation and the resultant inflammatory responses are important contributors to the problems of sickle cell disease. Sickle cell disease has been referred to both as a condition associated with increased risk of blood clots and increased inflammation. A painful crisis represents the most common cli nical problem in sickle cell disease, but the treatment of these crises remains inadequate.
Interventions
- DRUG Placebo
- DRUG Eptifibatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00834899
The ClinicalTrials.gov registry entry for NCT00834899 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00834899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00834899 about?
NCT00834899 is a clinical study titled "A Safety Study of Eptifibatide in Patients With Sickle Cell Disease". This study will evaluate the safety of eptifibatide in sickle cell patients and how well it works during the course of painful crises. The overall hypothesis that we seek to test is that increased platelet activation and the resultant inflammatory responses are important contributors to the problems...
What is the current status of trial NCT00834899?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2009-01. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00834899?
The interventions under investigation include: Placebo (DRUG), Eptifibatide (DRUG).
Who is sponsoring clinical trial NCT00834899?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.